The Individualized Behavioral Intervention of Smartphone App in the Treatment of Type 2 Diabetes Mellitus
A Multicenter, Prospective, Randomized, Controlled Clinical Trial of the Individualized Behavioral Intervention of Smartphone App in the Treatment of Type 2 Diabetes Mellitus
Sponsor: H & J CRO International, Inc.
This NA trial investigates Diabetes Mellitus, Type 2 and is currently ongoing. H & J CRO International, Inc. leads this study, which shows 7 recorded versions since 2017 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Study Description(click to expand)This study enrolled 400 patients with type 2 diabetes in five centers in Shandong Province, China. Patients with type 2 diabetes who met the inclusion / exclusion criteria were randomly assigned to the trial group (conventional treatment + maltose app) or the control group (conventional treatment) in a 1: 1 ratio.
The control group: given conventional hypoglycemic drug treatment, the treatment plan by the investigators according to the patient's condition may be, this study does not interfere.
The trial group: the patients were treated with conventional hypoglycemic drugs. The treatment plan was decided by the researcher according to the patient's condition. The intervention was not done in this study.
Interventions include:
1. Weekly diabetes-related science articles.
2. Patients reported hypoglycemia or other adverse reactions, the competent physician to deal with.
3. Questionnaires published out the hospital (2 weeks 1), the feedback for the problem.
4. monitoring of abnormal blood glucose data or the presence of related discomfort, can communicate with the competent physician online.
5. Personalize the development of diet, exercise program.
6. different insulin and oral hypoglycemic drug medication time to remind.
7. hypoglycemic drug side effects query.
This study enrolled 400 patients with type 2 diabetes in five centers in Shandong Province, China. Patients with type 2 diabetes who met the inclusion / exclusion criteria were randomly assigned to the trial group (conventional treatment + maltose app) or the control group (conventional treatment) in a 1: 1 ratio.
The control group: given conventional hypoglycemic drug treatment, the treatment plan by the investigators according to the patient's condition may be, this study does not interfere.
The trial group: the patients were treated with conventional hypoglycemic drugs. The treatment plan was decided by the researcher according to the patient's condition. The intervention was not done in this study.
Interventions include:
1. Weekly diabetes-related science articles. 2. Patients reported hypoglycemia or other adverse reactions, the competent physician to deal with. 3. Questionnaires published out the hospital (2 weeks 1), the feedback for the problem. 4. monitoring of abnormal blood glucose data or the presence of related discomfort, can communicate with the competent physician online. 5. Personalize the development of diet, exercise program. 6. different insulin and oral hypoglycemic drug medication time to remind. 7. hypoglycemic drug side effects query.
Status Flow
Change History
7 versions recorded-
Jan 2026 — Present [monthly]
Unknown NA
-
Sep 2024 — Present [monthly]
Unknown NA
-
Jul 2024 — Sep 2024 [monthly]
Unknown NA
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status NA
-
Mar 2019 — Jan 2021 [monthly]
Unknown Status NA
Status: Recruiting → Unknown Status
▶ Show 2 earlier versions
-
Jun 2018 — Mar 2019 [monthly]
Recruiting NA
-
Mar 2017 — Jun 2018 [monthly]
Recruiting NA
First recorded
Jan 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- H & J CRO International, Inc.
- Qingdao Zhixin Health Technology Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .